Citadel Advisors
LBRX

Citadel Advisors’s LB Pharmaceuticals LBRX Stock Holding History

Citadel Advisors’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.01M Sell
215,969
-200,937
-48% -$5.9M ﹤0.01% 4153
2026
Q1 		$10.3M Buy
416,906
+9,238
+2% +$213K ﹤0.01% 3217
2025
Q4 		$9.07M Sell
407,668
-131,702
-24% -$2.3M ﹤0.01% 3391
2025
Q3 		$8.52M Buy
+539,370
New +$8.56M ﹤0.01% 3501

Other funds holding LBRX

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Citadel Advisors's LBRX Position: Q2 2026 in Review

Citadel Advisors reduced its LB Pharmaceuticals (LBRX) stake by 48% in Q2 2026, selling an estimated $5.9M and leaving 215,969 shares worth $7.01M. The position accounts for ﹤0.01% of the portfolio, ranked #4153.

Citadel Advisors first reported a position in LBRX in Q3 2025 and has held it in 4 quarters since. The position peaked at $10.3M in Q1 2026. 115 funds tracked by Wall St. Rank hold LBRX as of Q2 2026.

  • Citadel Advisors held 215,969 shares of LB Pharmaceuticals worth $7.01M as of Q2 2026.
  • Citadel Advisors sold 200,937 LB Pharmaceuticals shares in Q2 2026, an estimated $5.9M.
  • LB Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #4153 holding.
  • Citadel Advisors first reported a position in LB Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Citadel Advisors's LB Pharmaceuticals position peaked at $10.3M in Q1 2026.
  • 115 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.